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Vitamin D is important for bone health, but may also have extra-skeletal effects. Vitamin D
and its binding protein DBP have immunological effects and may therefore be important
in the development of type 1 diabetes (T1DM), and low serum levels of 25-hydroxyvitamin
D (25(OH)D) are associated with later development of type 2 diabetes (T2DM). However,
it has so far been difficult to convincingly show an effect of vitamin D supplementation
on prevention or treatment of diabetes. The serum level of 25(OH)D has traditionally
been used as a marker of a subject’s vitamin D status. This measurement includes both
25(OH)D bound to DBP and albumin as well as the free from of 25(OH)D. However,
according to the free hormone hypothesis, the free form is the biologically active.
Previously the free form of 25(OH)D had to be calculated based on measurements
of 25(OH)D, DBP, and albumin, but recently a method for direct measurement of free
25(OH)D has become commercially available. This is important in clinical conditions
where the amount of DBP is affected, and has caused a renewed interest in which vitamin
D metabolite to measure in clinical situations. In the present review the relations between
DBP, total and free 25(OH)D in T1DM and T2DM are described.
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INTRODUCTION
Vitamin D is produced in the skin upon UV-B exposure and is obtained through the diet where
fatty fish is the main source. Regardless of how it is obtained, vitamin D has to be hydroxylated
first in the liver to 25-hydroxyvitamin D (25(OH)D) and then in the kidneys to the active form
1,25-dihydroxyvitamin D (1,25(OH)2D) (1). These hydroxylations may also occur in peripheral
tissues (2).
In the circulation the major part of vitamin D, 25(OH)D and 1,25(OH)2D are bound to the
vitamin D binding protein (DBP), and to a lesser extent also to albumin. Only a small fraction
circulates in the free form (3). To exert their action, the vitamin Dmetabolites have to cross the cell
membrane into the cell [and for vitamin D and 25(OH)D also to be hydroxylated], where the active
form 1,25(OH)2D connects to the nuclear vitamin D receptor (VDR) (1).
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The endocytic receptors megalin and cubulin are present in
the renal tubuli and parathyroid cells (4), and at least in the
kidney enable transportation of the DBP-vitamin D complexes
into the cells (5). In other (and perhaps most) cell types, the
vitamin D metabolites have to pass the cell membranes in their
free un-bound form by passive diffusion (6).
The serum concentrations of vitamin D and 25(OH)D are
>100 times that of 1,25(OH)2D, and the DBP binding coefficients
as well as the potential for passive diffusion through cell
membranes differ between these vitamin D metabolites (6).
Accordingly, it is difficult to say which vitamin D metabolite,
or vitamin D metabolite-DBP complex is quantitatively the
most important for VDR activation and the one that should be
measured for evaluation of a subject’s vitamin D status (6, 7).
For this purpose, one has traditionally measured the serum
25(OH)D level, since this metabolite is abundant, easy to
measure, and has a long half-life and therefore stable levels.
Furthermore, the hydroxylation from vitamin D to 25(OH)D is
substrate driven and the serum 25(OH)D level correlates strongly
with sun exposure and vitamin D intake and also correlates with
known vitamin D effects, like the suppression of the parathyroid
hormone (PTH) secretion (1).
The serum 25(OH)D that is measured is the total 25(OH)D,
which includes the DBP and albumin bound 25(OH)D as well
as the free form. Since the major part of 25(OH)D is bound
to DBP, the concentration of total 25(OH)D will depend on
the serum DBP concentration. The DBP concentration is fairly
stable throughout life, but increases with pregnancy and estrogen
supplementation. DBP is synthesized in the liver and accordingly
the serum DBP concentration is reduced in liver failure as well
as in malnutrition (8, 9). Loss of proteins in the urine (like in
some subjects with diabetes) may also cause low serum DBP
levels (10, 11). Thus, in situations with high serum DBP levels
like pregnancy, an even larger portion of the total 25(OH)D in
plasma is bound to DBP and accordingly the free form is reduced.
Conversely, in patients with liver cirrhosis where the serum level
of DBP is low, the free fraction is increased. Although there
is a strong correlation between total and free 25(OH)D (12),
measurement of total 25(OH)D may therefore not always reflect
the free form.
According to the free hormone hypothesis, it is the free form
of the hormone, which easily diffuses through cell membranes,
that is the biologically active, and the one to be measured (13).
This is exemplified for thyroid hormones, where the serum
concentration of tree thyroxine is regulated in a negative feedback
manner by the secretion of thyroid stimulating hormone (TSH).
In this system, changes in the concentration of thyroid hormone
binding globulin (TBG) will be compensated by increased or
decreased secretion of TSH keeping the free concentration of
thyroxine stable (14). This demonstrates the utility of the free
hormone concept for thyroid hormones.
This concept does not necessarily apply to the vitamin
D system where the active hormone 1,25(OH)2D can be
transported into (at least some) cells in a DBP-complex,
and also have its activating hydroxylations intracellularly.
Furthermore, 25(OH)D is in essence a pro-hormone not
regulated by negative feed-back control. Changes in DBP will
not induce changes in the hydroxylation of vitamin D to
25(OH)D since this is a substrate driven process. Increased
serum 25(OH)D concentrations may be accompanied by an
increased level of FGF-23, increasedCYP24A1 expression and 24-
hydroxylase activity, and accelerated degradation of 25(OH)D to
24,25(OH)2D (15). However, this mechanism must for 25(OH)D
be of minor importance since the increase in free 25(OH)D
and total 25(OH)D after vitamin D supplementation is, at least
until serum 25(OH)D levels of approximately 150 nmol/L, quite
linear (12). Therefore, whether the total or the free form of
25(OH)D is the best vitamin D parameter cannot be decided on
theoretical grounds only, but has to be tested in clinical situations
as well (16, 17).
There are many single nucleotide polymorphisms (SNPs) in
the DBP gene (GC gene, globulin–complex gene). Combinations
of two of these (rs7041 and rs4588) result in three polymorphic
alleles and six major phenotypes. These phenotypes may have
different binding affinities for the vitamin D metabolites (18)
and the serum 25(OH)D levels do differ between subjects with
different DBP phenotypes (12). The distribution of the six
variants also differs between races (19).
In addition to the skeleton vitamin D deficiency has
been associated with a number of diseases, like mortality,
cancer, immunological diseases, cardio-vascular diseases,
and diabetes (20). Most of these relations are based on
observational studies only, where 25(OH)D has been measured
in old serum samples and subsequent diseases recorded.
For these studies, measurement of total serum 25(OH)D
has been employed, whereas there has been little focus on
DBP [where the major part of the circulating 25(OH)D
is bound] or the free form which potentially may be the
most important.
The serum level of free 25(OH)D has traditionally been
calculated based on measurements of total 25(OH)D, DBP,
and albumin concentrations (21–23). However, measurement
of DBP depends on type of antibody employed (monoclonal
or polyclonal) (19), and it has usually been assumed that the
vitamin D binding-coefficient for each of the six prevalent
DBP phenotypes are equal. The validity of the free 25(OH)D
calculations have therefore been questioned (24). Lately, kits for
direct measurement free 25(OH)D has become commercially
available which has caused a renewed interest in the relation
between free serum 25(OH)D, as well as DBP, and disease states
(25). However, further validation and standardization of this
assay is still needed in subjects with major illnesses or with
abnormal DBP or protein concentrations (16).
In the present review these relations will be summarized for
the metabolic disorders type 1 and type 2 diabetes (T1DM and
T2DM), presented separately.
T2DM
Serum 25(OH)D and T2DM
There are many reasons for why vitamin D could influence
the development of T2DM. Thus, the vitamin D activating
hydroxylases and the VDR are found in the pancreatic beta-
cells (26, 27), 1,25(OH)2Dmay induce insulin secretion (28), and
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vitaminDmay have an anti-inflammatory effect thatmay prevent
insulin resistance (29).
In line with this, there are a number of observational studies
on the relation between serum 25(OH)D concentration and
incident diabetes, and practically all confirm an association
(30). Thus, in a study by Afzal et al. on 31,040 subjects with
measurement of serum 25(OH)D followed for up to 34 years,
participants who had a 20 nmol/L reduction in 25(OH)D had a
16% increased risk of T2DM (31). Similarly, Ye et al. combined
22 studies in a meta-analysis that included 8,492 cases and 89,698
controls and found a 21% increased risk of T2DM per 25 nmol/L
lower 25(OH)D concentration (32).
However, for vitamin D there is a strong possibility of revers
causation and other methods than observational studies are
needed for confirmation, as recently reviewed by Angelotti and
Pittas (30).
There are a few RCTs with vitamin D specifically designed
for prevention of T2DM in subjects at risk. Thus, Davidson
et al. included 109 subjects with prediabetes and randomized
them to high dose vitamin D (mean weekly dose 88,865 IU)
vs. placebo. However, no significant effects on insulin secretion,
insulin sensitivity or development of diabetes were found after
1 year (33). Similarly, in a study from Tromsø, Norway,
Jorde et al. randomized 511 subjects with reduced glucose
tolerance to 20,000 IU vitamin D per week vs. placebo for
a maximum of 5 years, but found no difference between the
groups in development of T2DM (34). However, both studies
were underpowered for detection of minor effects. And finally,
the effect of giving vitamin D to subjects with established
T2DM do at best show a marginal effect on HbA1c with a
reduction of 0.32% inHbA1c as comparedwith placebo according
to a review by Lee et al. that included nine trial with 3,324
participants (35).
Another approach to the vitamin D—T2DM question is
the Mendelian randomization. Several SNPs are associated
with serum 25(OH)D level; SNPs in the DHCR7 gene
related to vitamin D synthesis, the CYP2R1 gene related
to 25-hydroxylation, and the CYP24A1 gene related to 24-
hydroxylation and degradation (36). When these SNPs are
combined to a genetic score, the highest vs. the lowest
scores result in 5–20% difference in serum 25(OH)D levels.
However, in the most recent and largest meta-analysis including
five studies with 28,144 cases and 76,344 non-cases, no
significant association with T2DM was found, neither for
the individual SNPs tested, nor when combined to a genetic
score (32).
There are, however, many shortcomings of the Mendelian
randomization approach. So far it only predicts differences in
serum 25(OH)D concentration and not the free fraction, and the
alleles tested only explain a small part of the variance in serum
25(OH)D level.
One may therefore conclude that although a low serum
25(OH)D level do predict development of T2DM, this is most
likely due to confounding or reverse causality, although minor
effects cannot be excluded. Hopefully the ongoing D2d study that
has included 2,423 participants with prediabets randomized to
4000 IU vitamin D daily vs. placebo may settle this question (37).
Free 25(OH)D and T2DM
There are several reports where the directly measured free
fraction of 25(OH)D has been compared with total 25(OH)D
regarding biological effects of vitamin D. Thus, Johnsen et al.
found a better correlation for free than for total 25(OH)D
regarding bone density (24), whereas that was not found in study
by Michaelsson et al. (38). For PTH similar relations have been
found for free and total 25(OH)D in most studies (24, 39–41),
whereas Lopez-Molina et al. in healthy children found better
correlation with markers of phosphocalcic metabolism for free
than for total 25(OH)D (42). Shieh et al. found in the early phase
(first 4 weeks) of vitamin D treatment the free 25(OH)D, but not
the total 25(OH)D, to be associated with a decrease in serum PTH
(43). In inflammatory diseases the results are also mixed with
free 25(OH)D correlating better to disease activity in ulcerative
colitis (44), whereas total 25(OH)D correlates best to activity in
systemic lupus erythematosus (45). For markers of inflammation
(IL-6) in older men free and total 25(OH)D appear to correlate
equally (46). And finally and most important, in a study by Yu
et al. the free but not total 25(OH)D was associated with risk
of mortality in patients with coronary artery disease (47). The
study included 1,387 patients followed for a median time of
6.7 years, during which period 205 patients died. The all-cause
mortality was 64% higher in the lowest free 25(OH)D quartile
vs. the highest free 25(OH)D quartile, whereas the corresponding
analysis using 25(OH)D did not show a significant difference or
trend across the quartiles.
So far, there are no studies where the free 25(OH)D has been
compared with total 25(OH)D as predictor for development of
T2DM. However, there is a publication by Lee et al. that included
1,189 non-diabetic subjects where the free and total form of
25(OH)D were measured and related to acute insulin response
and glucose disposition index based on intravenous glucose
tolerance tests (48). Both free and total 25(OH)D were positively
associated with these measures, but after adjustment for BMI,
only free 25(OH)D was significant related to insulin secretion.
Based on the above papers, one cannot conclude that
measurements of free vs. total serum 25(OH)D has any advantage
regarding vitamin D responses. This is also difficult to decide,
as comparisons of P-values and correlation coefficients give
indications only.
DBP and T2DM
In addition to being the carrier protein for vitamin D and its
metabolites, DBP has a number of other effects. It acts as a
carrier for free fatty acids (49), it binds actin and may prevent
actin polymerization during tissue damage (50, 51), may act as a
macrophage activator and play a part in the inflammation process
by influencing the T-cell response (52). These immunological
effects may differ between the phenotypes (53), and the level of
DBP as well as the different DBP phenotypes might therefore at
least theoretically affect the development of not only T1DM (see
later) but also T2DM.
However, in a case-cohort study design with 958 cases and
3,489 controls Jorde et al. found no association between DBP
phenotypes (based on genotyping of rs4588 and rs7041) and
incident T2DM (54). Furthermore, there were no relations
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between the DBP phenotypes and lipids and blood pressure, but
a slight relation to hip circumference.
Prior to our study Wang et al. made a meta-analysis on
DBP SNPs and T2DM that included six studies (three Caucasian
and three Asian cohorts) with 1,191 cases and 882 controls. No
overall association between theDBP SNPs rs4588 and rs7041 and
T2DM was found. However, when analyzing the Asian cohorts
separately, there were significant associations with T2DM for
both rs7041 and rs4588 (55).
Also after the meta-analysis by Wang et al., Ye at al.
meta-analyzed the DBP SNP rs4588 regarding T2DM in
European cohorts including 28,144 cases and 76,344 controls.
A strong relation between rs4588 and serum 25(OH)D was
found, but not with T2DM (OR 1.00 (CI, 0.97 −1.03)
(32). Accordingly, at least in Caucasians there appears to
be no relation between DBP phenotypes and development
of diabetes.
To the author’s knowledge, there are no longitudinal studies
regarding serum levels of DBP and T2DM. However, there is
one cross-sectional study by Leong et al. on 2,122 adult subjects
that included 201 with diabetes (56). The effect estimate per 50
mg/L DBP increase was 0.79 (95% CI 0.65–0.96) for diabetes,
and there was a marginal relation between higher DBP and lower
fasting blood glucose levels. However, as a cross-sectional study
it could not examine the impact of biological variability of DBP
over time.
T1DM
Serum 25(OH)D and T1DM
The 1α-hydroxylase, necessary for activation of vitamin D, is
expressed in immune cells like the B- and T-cells and the
antigen presenting cells (2). These cells may therefore synthesize
active vitamin D locally. Vitamin D has immune-modulatory
effects (57), and since T1DM is an autoimmune disorder, a
role for vitamin D in pathogenesis as well as treatment thus
possible (58).
However, in a study by Thorsen et al. using a case-cohort
design that included 459 children with T1DM and a control
group of 1,561, no association betweenmaternal serum 25(OH)D
levels sampled repeatedly during pregnancy and subsequent
T1DM in the offsprings was found (59). Furthermore, in two
large Danish populations, one case-cohort study with 912 cases
and 2,866 controls followed for a maximum of 31 years and
a case-control study with 527 matched pairs followed for a
maximum of 23 years, Jacobsen et al. found no relation between
neonatal vitamin D status and later risk of T1DM (60). On the
other hand, there might be a link between intake of vitamin D in
childhood and development of T1DM as reported by Hyppönen
et al. in a birth-cohort study with 12,055 pregnant women in
northern Finland (61). This was also the conclusion in a meta-
analysis by Dong et al. from 2013 that included eight studies
(six case-control and two cohort studies) with vitamin D intake
during early life where the pooled OR for T1DM was 0.71 (95%
CI, 0.51–0.98) (62).
Furthermore, the serum levels of 25(OH)D are lower in
subjects with newly diagnosed T1DM (63) as well as later in the
course of disease compared to similarly aged subjects (64). There
may also be a beneficial effect by vitamin D supplementation
in newly diagnosed T1DM. This was reviewed by Gregoriou
et al. (65) who found a positive effects on the daily insulin dose,
fasting, and stimulated C-peptide response by vitamin D in two
studies. However, only 67 patients were randomized and the
effect was marginal.
To the author’s knowledge there are no studies reporting free
25(OH)D levels in T1DM.
DBP and T1DM
Since the immunological effects of DBP may differ between the
DBP phenotypes (53), relations between the DBP SNPs rs4588
and rs7041 and T1DM are of interest. This was reviewed by
Penna-Martinez and Badenhoop who found that in the majority
of the studies there was no relation between these SNPs and
T1DM (66). As an example, Cooper et al. who included 720
cases and 2,610 controls and used a Mendelian randomization
approach, found no relation between rs4588 and T1DM (67),
whereas in the two studies that did find an associationwith rs7041
the total number of cases was only 154 (68, 69).
There are a few cross-sectional reports on serum DBP levels
in patients with T1DM. In a study by Blanton et al. that
included 203 subjects with T1DM and 153 controls, the serum
DBP levels were ∼10% lower in the T1DM patients (70). A
similar result was found by Thraikill et al. but they could for
a large part ascribe this to increased urinary loss of DBP in
the urine (11). Low serum DBP levels have also been described
in diabetic BB rats together with low serum 1,25(OH)2D
levels accompanied with reduced duodenal calcium absorption,
indicating the possible physiological importance of urinary DBP
loss (71).
CONCLUSIONS
For preventing or treating diabetes, the majority of clinical
studies do not indicate a major role for vitamin D
supplementation, with a possible exception for T1DM in
children. As for many other presumed extra-skeletal effects
of vitamin D, the effect on glucose metabolism must be small
(if present at all) and accordingly difficult to demonstrate. In
most of the vitamin D RCTs the results are also hampered by
the inclusion of subjects who are not truly vitamin D deficient
(72). However, since such subjects (and in particular young
children) need vitamin D for bone health, there are many ethical
problems in including vitamin D deficient subjects in long lasting
RCTs. The “perfect” vitamin D RCT will therefore probably not
be performed.
However, regarding vitamin D and health, the two crucial
questions are how much vitamin D we need for skeletal
health (which everyone agrees is vitamin D dependent),
and if supplementation above that will give any additional
health benefits.
So far, there are too few studies on the relative importance
of measuring total or free 25(OH)D in diabetes and glucose
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metabolism, and too few studies on the importance of DBP
concentration on development and progression of diabetes, to
draw firm conclusion. However, since it is difficult to show
an effect of vitamin D supplementation regarding diabetes, it
follows that finding the right form or metabolite of vitamin D
to measure (7), may for diabetes simply be a search for another
biomarker (73). In disease states with clearly altered DBP levels,
like pregnancy and liver cirrhosis, the situation obviously is
different (9).
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